Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study
The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
Popular Weight Loss Drugs Ozempic, Wegovy May Lower Alzheimer's Disease Risk
Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a
Novo’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Ozempic linked to lower Alzheimer’s risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study
In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.
3h
Breakthrough Discovery: Freezing Alzheimer’s Progress by Pausing Amyloid Fibrils
Researchers have identified a key mechanism in the development of Alzheimer's disease involving the growth and pause of ...
5d
on MSN
New Alzheimer’s research reveals ‘quiet’ phase of the disease, before symptoms appear
New details have emerged into how Alzheimer’s disease affects the brain. Researchers have identified cellular changes in the ...
ScienceAlert on MSN
5d
Alzheimer's Disease Harms The Brain in 2 Distinct Phases, Study Reveals
An analysis of the genetic activity of brain cells in individuals who have died with Alzheimer's disease has revealed the ...
Psychology Today
3d
Early Signs of Alzheimer’s Disease? Follow the Money
As our family members age, we worry. We worry about their physical health and potential cognitive declines. If you are ...
WWLP Springfield on MSN
4d
Walk to End Alzheimer’s in Holyoke to raise funds to end disease
The Alzheimer's Association Massachusetts-New Hampshire Chapter is fighting the disease at the Pioneer Valley Walk to End ...
health enews
19h
Do’s and don’ts: Caring for a loved one with Alzheimer’s disease
When caring for a loved one with Alzheimer’s disease, be patient and repeat when necessary, plan ahead and use memory cues.
14h
Scientists Uncover How Brain Injuries Could Trigger Alzheimer’s
Researchers have discovered that traumatic brain injuries (TBI) may increase the risk of developing Alzheimer’s disease. By ...
1d
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Novo Nordisk
United Kingdom
drugs
Massachusetts
Feedback